TIGIT antibodies, encoding nucleic acids and methods of using said antibodies in vivo

An antibody or fragment that comprises one or more TIGIT binding sites, wherein each binding site specifically binds to TIGIT and comprises a heavy chain variable (VH) domain and a light chain variable (VL) domain;

• wherein:
• (a) the VH domain comprises an amino acid sequence at least 85% identical to SEQ ID NO:603 and the VL domain comprises an amino acid sequence at least 85% identical to SEQ ID NO:613;
• (b) the VH domain comprises an amino acid sequence at least 85% identical to SEQ ID NO:623 and the VL domain comprises an amino acid sequence at least 85% identical to SEQ ID NO:633;
• (c) the VH domain comprises an amino acid sequence at least 85% identical to SEQ ID NO:643 and the VL domain comprises an amino acid sequence at least 85% identical to SEQ ID NO:653;
• or
• (d) the VH domain comprises an amino acid sequence at least 85% identical to SEQ ID NO:663 and the VL domain comprises an amino acid sequence at least 85% identical to SEQ ID NO:673;
• and
• wherein:
• (i) the VH domain of the antibody or fragment comprises the CDRH3 sequence of SEQ ID NO:599 or 602, the CDRH2 sequence of SEQ ID NO:598 or 601, and the CDRH1 sequence of SEQ ID NO:597 or 600;
• and the VL domain of the antibody or fragment comprises the CDRL3 sequence of SEQ ID NO:609 or 612, the CDRL2 sequence of SEQ ID NO:608 or 611, and the CDRL1 sequence of SEQ ID NO:607 or 610;
• (ii) the VH domain of the antibody or fragment comprises the CDRH3 sequence of SEQ ID NO:619 or 622, the CDRH2 sequence of SEQ ID NO:618 or 621, and the CDRH1 sequence of SEQ ID NO:617 or 620;
• and the VL domain of the antibody or fragment comprises the CDRL3 sequence of SEQ ID NO:629 or 632, the CDRL2 sequence of SEQ ID NO:628 or 631, and the CDRL1 sequence of SEQ ID NO:627 or 630;
• (iii) the VH domain of the antibody or fragment comprises the CDRH3 sequence of SEQ ID NO:639 or 642, the CDRH2 sequence of SEQ ID NO:638 or 641, and the CDRH1 sequence of SEQ ID NO:637 or 640;
• and the VL domain of the antibody or fragment comprises the CDRL3 sequence of SEQ ID NO:649 or 652, the CDRL2 sequence of SEQ ID NO:648 or 651, and the CDRL1 sequence of SEQ ID NO:647 or 650;
• or
• (iv) the VH domain of the antibody or fragment comprises the CDRH3 sequence of SEQ ID NO:659 or 662, the CDRH2 sequence of SEQ ID NO:658 or 661, and the CDRH1 sequence of SEQ ID NO:657 or 660;
• and the VL domain of the antibody or fragment comprises the CDRL3 sequence of SEQ ID NO:669 or 672, the CDRL2 sequence of SEQ ID NO:668 or 671, and the CDRL1 sequence of SEQ ID NO:667 or 670.